Our biopharmaceutical research and development capabilities consist of three specialized platforms targeting a variety of biological therapies, including the ADC technology platform, the antibody discovery platform, and the advanced process and analytical development platform. This system serves as a solid foundational technology solution for discovering and developing next-generation ADC and immuno-oncology candidates.
MRG003 EGFR-targeted ADC
≥2L NPC (nasopharyngeal cancer)
≥2L HNSCC (head and neck squamous cell carcinoma)
MRG002 HER2-targeted ADC
BC (breast cancer) HER2 (human epidermal growth factor receptor 2) over-expressing
UC (urothelial cancer)
MRG004A TF-targeted ADC
TF-positive(tissue factor positive)advanced or metastatic solid tumors
MRG001 CD20-targeted ADC
NHL(non-Hodgkin's lymphoma)
CTR20190851
CMG901 CLDN18.2-targeted ADC
Solid tumors
Advanced G/GEJ carcinoma
HX008 Anti-PD-1 mAb
≥2L MSI-H/dMMR (high levels of microsatellite instability/ deficient mismatch repair) solid tumors
≥2L Melanoma
2L advanced G/GEJ carcinoma
CTR20181269/NCT03704246
CTR20181881/NCT04749485
CTR20201055/NCT04486651
CG0070 Oncolytic virus
BCG-unresponsive (bacillus calmette-guerin unresponsive) NMIBC (non-muscle invasive bladder cancer)
PUYOUHENG (Pucotenlimab Injection) +MRG003
EGFR positive solid tumors
PUYOUHENG (Pucotenlimab Injection) +MRG002
HER2-expressing solid tumors
CG0070 + PUYOUHENG (Pucotenlimab Injection)
NMIBC(non-muscle invasive bladder cancer)BCG-unresponsive(bacillus calmette-guerin unresponsive)
LP010 Tigit mAb
PD1/L1 relapsed/refractory solid tumor
LP008 PDL1-TGFbRII
PD1/L1 relapsed/refractory solid tumor
MRG 006A target undisclosed
Solid tumors
We have manufacturing sites in Beijing and Shanghai. Our manufacturing plant in Beijing houses a 2,000L GMP-compliant antibody production line in operation and an oncolytic virus production line under construction with a designed capacity of 200L. We are also building up a biologics manufacturing plant in Shanghai Biotech Park with laboratories and manufacturing facilities, which will house two production lines with a designed capacity of 6,000L each.In October 2022, our research and development center in the Shanghai Biotech Park was put into operation.
A 2,000L antibody production line came into operation in 2019 with 13,442 sq.m of floor space in support of clinical trials for our Company’s antibody products. This facility was issued a drug manufacturing license by the Beijing Municipal Medical Products Administration. In addition, an oncolytic virus production line is currently under construction with a designed capacity of 200L.
We are building manufacturing facilities in the Shanghai Biotech Park. The first phase has a designed total capacity of 12,000L, and one production line with capacity of 6,000L is under construction.
Product | Applicant Patentee | Title of Patent/Patent Application | Jurisdiction | Commercial Rights |
HX008 | Taizhou Hanzhong and Akeso | Anti-PD-1 Monoclonal Antibody | Mainland China | All rights in Mainland China |
Taizhou Hanzhong and Akeso | Monoclonal Antibody Resisting Against PD-1 and Applications Thereof | Mainland China | All rights in Mianland China | |
Taizhou Hanzhong and Akeso | Monoclonal Antibody Resisting Against PD-1 and Applications Thereof | U.S., European Union | All rights in the related jurisdictions | |
Taizhou Hanzhong and Akeso | Anti-PD-1 monoclonal antibody | PCT (Japan, U.S and European Union) | All rights in related jurisdictions | |
Han X | Method for increasing binding affinity of IGG-Like antibody to FcRn and prolonging serum half-life period thereof | PCT (Japan) | Non-exclusive license to develop and commercialize in Japan | |
LP002 | I-Mab Shanghai | Anti-PD-L1 and thereof | Mainland China | Exclusive license to develop and commercialize in Mainland China |
I-Mab Shanghai | Anti-PD-L1 Antibodies and Uses Thereof | PCT (Mainland China, US, South Korea, Japan, Australia, Chile, Colombia, Indonesia, Israel, New Zealand) | Exclusive license to develop and commercialize in related jurisdictions | |
MRG003 | Miracogen Shanghai | Antibody-Drug Conjugate | Mainland China | All rights in Mainland China |
Miracogen Shanghai | Antibody-Drug Conjugate | U.S. | All rights in the U.S. | |
JMT | Humanized antibody against epidermal growth factor receptor and application thereof | Mainland China | Exclusive license to develop and commercialize in Mainland China | |
MRG004A (mAb TF) | Miracogen Shanghai and Fudan University | Antibody Targeted to TF, Preparation Method Thereof, and Use Thereof | Mainland China | All rights |
Miracogen Shanghai and Fudan University | Antibody Targeted to TF, Preparation Method Thereof, and Use Thereof | (U.S, Japan) | Joint development and technology transfer | |
MRG004A (ADC) | Miracogen Shanghai, Fudan University and SIMMCAS | Tissue Factor-Targeted Antibody-Drug Conjugate | Mainland China | All rights |
Miracogen Shanghai, Fudan University and SIMMCAS | Tissue Factor-Targeted Antibody-Drug Conjugate | PCT (Japan) | Joint development and technology transfer | |
ADC Platform | Synaffix | Fused Cyclooctyne Compounds and Their Use in Metal-Free Click Reactions | PCT (Mainland China, European Union, Japan, U.S., India) | Non-exclusive license to develop and commercialize in related jurisdictions |
Synaffix | Fused Cyclooctyne Compounds and Their Use in Metal-Free Click Reactions | PCT (U.S.) | Non-exclusive license to develop and commercialize in related jurisdictions | |
Synaffix | Enzymes for Trimming Of Glycoproteins | PCT (U.S.) | Non-exclusive license to develop and commercialize in related jurisdictions | |
Synaffix | Modified Antibody, Antibody-Conjugate and Process for the Preparation Thereof | PCT (Mainland China, European Union, Japan, U.S.) | Non-exclusive license to develop and commercialize in related jurisdictions | |
Synaffix | Modified Antibody, Antibody-Conjugate and Process for the Preparation Thereof | PCT (U.S.) | Non-exclusive license to develop and commercialize in related jurisdictions | |
Synaffix | Process for the Modification of a Glycoprotein Using a Glycosyltransferase that is or is Derived from a ß(1,4)-N- Acetylgalactosaminyl transferase | PCT (European Union, U.S., Japan) | Non-exclusive license to develop and commercialize in related jurisdictions | |
Synaffix | Sulfamide Linker, Conjugates Thereof, and Methods of Preparation | PCT (Mainland China, European Union, Japan, U.S.) | Non-exclusive license to develop and commercialize in related jurisdictions | |
Synaffix | Sulfamide Linker, Conjugates Thereof, and Methods of Preparation | PCT (U.S.) | Non-exclusive license to develop and commercialize in related jurisdictions | |
Synaffix | Improved Sulfamide Linkers for Use in Bioconjugates | PCT (U.S.) | Non-exclusive license to develop and commercialize in related jurisdictions |